- Topic
30k Popularity
31k Popularity
21k Popularity
10k Popularity
19k Popularity
3k Popularity
33k Popularity
21k Popularity
33k Popularity
145k Popularity
- Pin
- 🎉 A Warm Welcome to Dr.Han on Gate Square!
Dr.Han — Founder of Gate and a seasoned crypto industry observer — is now officially sharing insights on Gate Square!
📢 Follow Dr.Han and like or comment on his latest post for a chance to win!
👉 Post: https://www.gate.com/post/status/11966645
👉 Profile: https://www.gate.com/profile/Dr_Han
🎁 Giveaway Alert:
We’ll randomly select 10 lucky users from those who follow + like/comment to receive a limited-edition Gate T-shirt — the same style worn by Dr.Han!
(If shipping is unavailable in your region, a $50 Futures Voucher will be provided instead.)
�
- 🔥 Gate Square #Gate Alpha Third Points Carnival# Trading Sharing Event is Live!
Share Alpha trading highlights screenshots with #Gate Alpha Trading Share# to split $100!
🎁 10 lucky users * 10 USDT each
📅 July 4, 4:00 – July 20, 16:00 UTC+8
Don’t forget—the main Alpha Points Carnival prize pool is up to $1,000,000!
Trade and post for double the chances to win!
Learn more: https://www.gate.com/announcements/article/45908
- 🎉 Gate xStocks Trading is Now Live! Spot, Futures, and Alpha Zone – All Open!
📝 Share your trading experience or screenshots on Gate Square to unlock $1,000 rewards!
🎁 5 top Square creators * $100 Futures Voucher
🎉 Share your post on X – Top 10 posts by views * extra $50
How to Participate:
1️⃣ Follow Gate_Square
2️⃣ Make an original post (at least 20 words) with #Gate xStocks Trading Share#
3️⃣ If you share on Twitter, submit post link here: https://www.gate.com/questionnaire/6854
Note: You may submit the form multiple times. More posts, higher chances to win!
📅 July 3, 7:00 – July 9,
- #GateSquareGiveaway# - Spot the Differences 👀
GM ☕ Our frog friend has two slightly different mornings—can you find all the changes?
💰 $10 Futures Voucher * 5 winners
To join:
🔹Follow Gate_Square
🔹Like this post and drop your answer in the comments
📅 Ends at 16:00 PM, July 7 (UTC)
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.